Adding baricitinib to standard-of-care in hospitalized patients with severe COVID-19 tied to survival benefit |
Journal Updates
eMediNexus Coverage from: 
Adding baricitinib to standard-of-care in hospitalized patients with severe COVID-19 tied to survival benefit

0 Read Comments                

A real-life study suggests that the addition of baricitinib to standard-of-care (SOC) among hospitalized COVID-19 patients with severe disease was tied to decreased mortality.This two-center, observational, retrospective cohort study included 369 patients with severe COVID-19, with a median symptom duration of 6 days. Overall, 176 (47.7%) patients received SOC, while baricitinib was added to SOC in 193 (52.3%) patients. Patients in the baricitinib plus SOC group had lesser odds of reaching the c...
To read the complete article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now